Summary
73 / 100 · Bulios Score
What speaks for it
- Out of every 100 INR of revenue, 16 INR is left as net profit.
- It earns 27 INR a year on every 100 INR of invested capital.
- Revenue grew by 16% a year over the last 3 years.
- It holds more cash than debt: ₹644.5M against ₹568.8M.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 5.5% a year over the last 3 years.
- It missed profit estimates 6 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 54.1 INR for 1 INR of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (INR)
Diluted EPS (INR)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 16% a year. Earnings per share fell by 5.5% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 INR of revenue goes
- Cost of sales 43 INR
- Sales and administration 32 INR
- Taxes and other 10 INR
- Net profit 16 INR
Net profit, industry median (Medical - Diagnostics & Research) 9.8 INR
Out of every 100 INR of revenue, 16 INR is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 1.43%
- Paid out of profit
- 77%
You receive ₹7.00 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail